krystal biotech corporate presentation

• News Releases
• Stock Information
• SEC Filings
• Corporate Governance
• Scientific Publications
• Email Alerts
• Analyst Coverage
• Investor FAQs

Krystal Biotech to Present at Upcoming Investor Conferences

PITTSBURGH , June 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the following upcoming investor conferences:

A live webcast of the presentations can be accessed on the Investors section of the Company’s website and an archived replay of each webcast will be available for approximately 30 days following the presentation.

About Krystal Biotech, Inc. Krystal Biotech , Inc. (NASDAQ: KRYS) is a fully integrated R&D and commercial biotechnology company focused on genetic medicines for patients with rare diseases. The Company has in-house GMP manufacturing and a wide-ranging pipeline that is powered by its proprietary, redosable HSV-1 gene delivery platform. VYJUVEK TM is the Company’s first commercial product and is the first-ever redosable gene therapy and the only medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. For more information, please visit  http://www.krystalbio.com , and follow @KrystalBiotech on LinkedIn and Twitter .

Meg Dodge Krystal Biotech [email protected]

Source: Krystal Biotech, Inc.

Transformative Gene Delivery Medicines

At Krystal, our focus is to bring transformative gene delivery medicines to patients with high unmet medical needs. The goal is to bring the promise of treatment to as many patients as possible who may benefit.

With a proven gene-delivery platform, Krystal is determined to change the way genetic diseases are treated using an industry-leading and first-in-class approach.

Krystal is the sum of individual parts. Each person has ownership to master a specific task or function, and when the entire team comes together, we become the aggregate of many refined components.   Krish S. Krishnan Chairman & CEO

Krystal is a company built and run by people who care, are fearless in the face of challenge, love the work they do, and pursue the highest level of scientific integrity. As we grow we seek leaders and scientists that embody these values   Suma Krishnan President, Research and Development

Learn more about Krystal’s experienced leadership team.

Board of Directors

Learn more about Krystal’s board of directors.

Join the Team

Explore the exceptional career opportunities at Krystal where we are united by a shared purpose and driven to make a difference.

Discovering, developing, and commercializing genetic medicines with purpose

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Newsletters
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• The Morning Brief
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds Rates
• Top Mutual Funds
• Options: Highest Open Interest
• Options: Highest Implied Volatility
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Stock Comparison
• Advanced Chart
• Currency Converter
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Credit Card Offers
• Best Free Checking
• Student Loans
• Personal Loans
• Car insurance
• Mortgage Refinancing
• Mortgage Calculator
• Editor's Picks
• Investing Insights
• Trending Stocks
• Morning Brief
• Opening Bid
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

In this article:.

PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference in Rancho Palos Verdes, California.

Krish Krishnan, Chairman and Chief Executive Officer, will represent the Company in a session scheduled at 10:40 am PDT on Wednesday, June 15.

A live webcast of the presentation will be available here and on the Investor section of the Company’s website .

About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com , and follow @KrystalBiotech on LinkedIn and Twitter .

CONTACTS: Investors and Media: Meg Dodge Krystal Biotech [email protected]

Source: Krystal Biotech, Inc.

Recommended Stories

We couldn’t find any results matching your search.

Please try using other words for your search or explore other sections of the website for relevant information.

We’re sorry, we are currently experiencing some issues, please try again later.

Our team is working diligently to resolve the issue. Thank you for your patience and understanding.

News & Insights

All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy

October 18, 2024 — 12:00 pm EDT

Written by Zacks Equity Research for Zacks  ->

Krystal Biotech, Inc. (KRYS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for Krystal Biotech basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For Krystal Biotech, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate Revisions

As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for Krystal Biotech

This company is expected to earn $2.38 per share for the fiscal year ending December 2024, which represents a year-over-year change of 186.2%.

Analysts have been steadily raising their estimates for Krystal Biotech. Over the past three months, the Zacks Consensus Estimate for the company has increased 45.3%.

Bottom Line

Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Krystal Biotech to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report

Krystal Biotech, Inc. (KRYS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks mentioned

More related articles.

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

To add symbols:

• Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
• Copy and paste multiple symbols separated by spaces.

These symbols will be available throughout the site during your session.

Your symbols have been updated

Edit watchlist.

• Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.

Opt in to Smart Portfolio

Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use .